Takeda agreed to fork over $8 million initially to Resolve as the startup works toward the start of first human studies in 2013 for the lead compound, RSLV-132, a nuclease Fc fusion protein. The deal includes backup compounds as well. And if planned Phase 1b/2a work for the front runner goes as hoped, Takeda could use its exclusive option from the deal and take over global development and commercialization of the compound, leading to up to $247 million in development payments to Resolve.
SJ Pharmaco is a consulting company which provides Drug safety compliance and pharmacovigilance services in US. Steve Jolley is a consultant in pharmacovigilance and drug safety with 25 years in the pharmaceutical industry. Our specialty is providing pharmacovigilance and drug safety consulting to companies that need help navigating global safety requirements for products.